About HCRx
HCRx is a Healthcare company based in Stamford (United States) founded in 2007, and was acquired by KKR in July 2025. Drugs for multiple therapeutic areas are manufactured through RD. Its chief executive, as recorded, is Dennis Lanfear. HCRx offers products and services including Royalty Monetization and Corporate Financing. Its focus areas include Diversified Pharmaceuticals. Its legal entity is HealthCare Royalty Management, LLC.
Company details
HCRx was established in 2007 and is headquartered in Stamford, United States. Research and development efforts are directed toward the manufacturing of drugs across various therapeutic areas within the pharmaceutical sector. Operations encompass drug production processes, with a focus on healthcare applications. Services are provided to support multiple medical fields, ensuring compliance with industry standards in the U.S. market.
Products & Services of HCRx
HCRx offers a comprehensive portfolio of products and services, including Royalty Monetization and Corporate Financing.
Acquires royalties for biopharmaceutical products to provide capital.
Offers funding solutions for biopharmaceutical companies and products.
Investors in HCRx
HCRx has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KKR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States |
Investor details for HCRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HCRx
19 people are tracked at HCRx (10 in leadership, 9 in team).
| Name | Role | Group |
|---|---|---|
Dennis Lanfear | CEO | Leadership |
Clarke Futch | CEO | Leadership |
Spencer Schneider | Chief Compliance Officer & Chief Patent Counsel | Leadership |
Carlos Almodóvar | Chief Business Officer | Leadership |
Collin Stewart | Vice President | Leadership |
Chris White | President & CFO | Leadership |
Tony Rapsomanikis | Senior Managing Director | Leadership |
Andrew Logerfo | Vice President | Leadership |
Josh House | Managing Director | Leadership |
Michele Romaniello | Senior Vice President, Operations | Leadership |
Marc Kozin | Chairman, Strategy Advisory Board | Team |
Timothy Bryant | General Counsel | Team |
Oluwasola Ogundare | Incoming Investment Management Intern | Team |
Rosa Mercado | Executive Assistant | Team |
Lauren Jorgensen | Executive Assistant | Team |
Julie McHugh | Strategic Advisor | Team |
Tolly Flinn | Senior Associate | Team |
David B. | Advisor EU And UK | Team |
Evan Bograd | Senior Associate | Team |
Complete people profiles for HCRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of HCRx
2 dated milestones of HCRx across 18 years, from founding to its latest funding, stage changes and deals.
- Founded HCRx is founded.
- Exit Acquired by KKR.
Web traffic of HCRx
The website of HCRx (hcrx.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 4% vs previous month
Websites whose visitors overlap most with HCRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| redhillbio.com | 100% | 5.7K | #4,631,827 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as HCRx (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hcrx
Complete news archive for HCRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HCRx
HCRx was founded in 2007.
HCRx is headquartered in Stamford, United States. It is registered at Stamford, Connecticut, United States.
Dennis Lanfear is the CEO of HCRx, as recorded in our data.
HCRx was established in 2007 and is headquartered in Stamford, United States. Research and development efforts are directed toward the manufacturing of drugs across various therapeutic areas within the pharmaceutical sector. Operations encompass drug production processes, with a focus on healthcare applications. Services are provided to support multiple medical fields, ensuring compliance with industry standards in the U.S. market.
HCRx offers Royalty Monetization and Corporate Financing.
HCRx has 1 investor. Key investors include KKR.
HCRx operates through Healthcare Royalty Management, Llc.
Yes. HCRx was acquired by KKR in July 2025.

